XSHG
603139
Market cap286mUSD
Jun 09, Last price
20.62CNY
1D
3.05%
1Q
33.03%
IPO
-10.66%
Name
Shaanxi Kanghui Pharmaceutical Co Ltd
Chart & Performance
Profile
Shaanxi Kanghui Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. It offers gynecological, orthopedic, dermatology, diabetes, respiratory system, urinary system, cardiovascular and cerebrovascular, gastrointestinal, hepatobiliary, and other drugs in the form of tablets, capsules, granules, mixtures, teas, plasters, ointments, liniments, lotions, and tinctures. The company is based in Xianyang, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 672,960 36.92% | 491,511 11.01% | |||||||
Cost of revenue | 646,749 | 451,689 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 26,212 | 39,823 | |||||||
NOPBT Margin | 3.89% | 8.10% | |||||||
Operating Taxes | (7,168) | ||||||||
Tax Rate | |||||||||
NOPAT | 33,380 | 39,823 | |||||||
Net income | (26,159) | ||||||||
Dividends | (7,391) | ||||||||
Dividend yield | 0.42% | ||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | 200,559 | 145,352 | |||||||
Long-term debt | 285,705 | 387,223 | |||||||
Deferred revenue | 35,247 | 36,013 | |||||||
Other long-term liabilities | 755 | 879 | |||||||
Net debt | 228,036 | 186,191 | |||||||
Cash flow | |||||||||
Cash from operating activities | 50,434 | ||||||||
CAPEX | (72,381) | ||||||||
Cash from investing activities | (45,965) | ||||||||
Cash from financing activities | 54,646 | 7,591 | |||||||
FCF | 79,247 | (97,859) | |||||||
Balance | |||||||||
Cash | 166,774 | 230,774 | |||||||
Long term investments | 91,454 | 115,609 | |||||||
Excess cash | 224,580 | 321,808 | |||||||
Stockholders' equity | 609,433 | 615,457 | |||||||
Invested Capital | 1,315,779 | 1,264,853 | |||||||
ROIC | 2.59% | 3.16% | |||||||
ROCE | 1.70% | 2.49% | |||||||
EV | |||||||||
Common stock shares outstanding | 100,610 | 99,880 | |||||||
Price | 18.77 5.75% | 17.75 -18.47% | |||||||
Market cap | 1,888,453 6.52% | 1,772,870 -18.47% | |||||||
EV | 2,187,176 | 2,011,279 | |||||||
EBITDA | 63,924 | 65,166 | |||||||
EV/EBITDA | 34.22 | 30.86 | |||||||
Interest | 23,461 | 13,218 | |||||||
Interest/NOPBT | 89.51% | 33.19% |